Zurich-based Rivia has raised a $15 million Series A led by Earlybird to accelerate its mission of transforming how clinical trials are run. At a time when trial data has become exponentially more complex and fragmented, Rivia is building a unified intelligence layer that structures data, applies scientific logic, and embeds AI agents directly into operational workflows.
As co-founder & CEO Erik Scalfaro shared in a recent conversation with Andreas and Earlybird Partner Dr. Christian Nagel, the problem is deeply rooted: clinical teams today still rely on hundreds of disconnected data sources, from patient records to wearable data, making even basic decisions difficult. Rivia’s approach brings this data together into a structured engine that enables real-time oversight, proactive decision-making and significant efficiency gains, already powering over 40 trials globally.
This foundation is what sets Rivia apart. Rather than layering AI on top of messy systems, the company started by building the underlying data infrastructure, creating what Earlybird sees as a defensible “data moat.” By tightly integrating data into workflows and continuously learning from each trial, Rivia’s platform becomes more valuable over time, delivering immediate ROI while compounding long-term advantage.
The impact is tangible. From preventing costly patient drop-offs to enabling earlier detection of trial issues, Rivia is helping teams shift from reactive to proactive operations—ultimately reducing costs and improving success rates. With 4x ARR growth in 2025 and fresh capital to scale its agentic product suite, Rivia is positioning itself as core infrastructure for the future of drug development.
Looking ahead, the ambition is bold: to enable leaner teams, faster trials, and a step-change in how new therapies reach patients—powered not by more manual effort, but by intelligent, scalable systems.
